Mirapex, Pramipexole News

Research and Markets: Commercial Insight: Parkinson's Disease - Japan and Europe to Drive Total Market Growth © Business Wire 2009 2009-10-29 03:05:03 - ) has announced the addition of the "Commercial Insight: Parkinson's Disease - Japan and Europe to Drive Total Market Growth" report to their offering.

Boehringer Ingelheim today announced that the Mirapexin /Sifrol new prolonged-release , once daily tablet has been granted marketing authorisation by the European Commission in all EU/EEA countries for the treatment of early and advanced idiopathic Parkinson's disease .

Five years after a small group of terminally ill patients pleaded with UVA for continued access to an experimental compound they believed could extend their lives, the UVA doctor who discovered the compound has left the university as mounting evidence suggests the drug is safe and, more importantly, that it may be effective against Amyotrophic ...

Boehringer Ingelheim announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has issued a positive opinion recommending the approval of a once daily formulation for Mirapexin/ Sifrol , in all countries of the European Union, Norway, Iceland and Liechtenstein.

Most of us take prescription drugs -- drugs that, by law, must be prescribed by a doctor -- at some point in our lives.

Arch Neurol. A 2009;66 :552-553. The Mirror Neuron System Cattaneo and Rizzolatti have discovered a class of neurons in the premotor cortex of monkeys that discharge both when individuals perform a given motor act and when they observe the same motor act performed by others.

Long-term Effect of Initiating Pramipexole vs Levodopa in Early Parkinson Disease Arch Neurol.

DRUGS USED TO TREAT Parkinson's disease have been linked to new-onset compulsive behaviors such as gambling or hypersexuality in a recent Mayo Clinic study.

First data showing outcomes of two double-blind studies investigating the efficacy, safety and tolerability of Mirapexin / Sifrol in a prolonged release, once daily formulation, for the treatment of Parkinson's disease , were presented at the American Academy of Neurology Annual Meeting in Seattle, U.S.A. The first study compared the efficacy, ...

Pharma Industry / Biotech Industry Results from an international, placebo-controlled trial,1 presented for the first time at the American Academy of Neurology Annual Meeting in Seattle, U.S.A. demonstrate that Mirapexin / Sifrol also improves depressive symptoms, a common, disabling non-motor symptom of Parkinson`s disease , in addition to its ...

Data indicated comparable efficacy and safety for extended release and immediate release formulations of pramipexole SEATTLE , April 29 /PRNewswire/ -- New findings from two double-blind studies investigating the efficacy, safety and tolerability of pramipexole dihydrochloride tablets in an extended release, once-daily formulation, for the ...

Main Category: Neurology / Neuroscience Also Included In: Sleep / Sleep Disorders / Insomnia New data presented at the 61st Annual Meeting of the American Academy of Neurology , in Seattle, U.S.A. show that augmentation did not significantly differ in RLS patients treated with Mirapexin /Sifrol versus the group receiving placebo.1Augmentation, i.e.